Fries Dietmar, Streif Werner, Margreiter Josef, Klingler Anton, Kühbacher Gabriele, Schobersberger Wolfgang, Wirleitner Barbara, Innerhofer Petra
Department of Anaesthesia and Critical Care Medicine, The Leopold-Franzens University of Innsbruck, Innsbruck, Austria.
Blood Coagul Fibrinolysis. 2004 Apr;15(3):213-9. doi: 10.1097/00001721-200404000-00003.
To explore whether intravenous administration of routinely used crystalloid or colloid solutions differently affects the coagulation system, we investigated orthopaedic patients. Since crystalloid solutions might cause hypercoagulability, we here present our results on molecular markers of coagulation and fibrinolysis. Patients undergoing knee replacement surgery randomly received isovolemic amounts of lactated Ringer's solution, 6% hydroxyethyl starch 200/0.5 or 4% modified gelatine. Arterial blood samples for determination of specific molecular markers of activated coagulation (thrombin/antithrombin complex, D-dimer, prothrombin fragment F1 + 2), fibrinolysis (plasmin/alpha 2-antiplasmin complex, tissue plasminogen activator, plasminogen activator inhibitor-1), and concentrations of coagulation factor XIII were obtained at baseline, before tourniquet release, at the end of surgery and 2 h after operation. During the observation period, thrombin/antithrombin complex increased from 4.8 to 54.7 microg/l, D-dimer increased from 0.3 to 6.0 mg/ml, prothrombin fragment F1 + 2 increased from 1.7 to 5.9 nmol/l, tissue plasminogen activator decreased from 7.3 to 6.7 ng/ml, plasminogen activator inhibitor-1 increased from 68.4 to 71.0 ng/ml, plasmin/alpha 2-antiplasmin complex increased from 281.5 to 884 microg/l and factor XIII decreased from 89.0 to 58.5%. All parameters changed significantly but without any detectable difference in the response profile between the groups receiving different intravenous fluids. During knee replacement surgery a pronounced activation of the coagulation/fibrinolytic system was observed, regardless of whether patients received crystalloid or colloid fluids. Thus, these results cannot confirm the hypothesis that crystalloid fluids per se cause hypercoagulability in vivo.
为探究静脉输注常规使用的晶体液或胶体液是否对凝血系统有不同影响,我们对骨科患者进行了研究。由于晶体液可能导致高凝状态,我们在此展示关于凝血和纤溶分子标志物的研究结果。接受膝关节置换手术的患者随机接受等容量的乳酸林格氏液、6%羟乙基淀粉200/0.5或4%改良明胶。在基线、止血带松开前、手术结束时及术后2小时采集动脉血样本,以测定活化凝血的特定分子标志物(凝血酶/抗凝血酶复合物、D - 二聚体、凝血酶原片段F1 + 2)、纤溶标志物(纤溶酶/α2 - 抗纤溶酶复合物、组织纤溶酶原激活物、纤溶酶原激活物抑制剂 - 1)以及凝血因子XIII的浓度。在观察期内,凝血酶/抗凝血酶复合物从4.8微克/升增至54.7微克/升,D - 二聚体从0.3毫克/毫升增至6.0毫克/毫升,凝血酶原片段F1 + 2从1.7纳摩尔/升增至5.9纳摩尔/升,组织纤溶酶原激活物从7.3纳克/毫升降至6.7纳克/毫升,纤溶酶原激活物抑制剂 - 1从68.4纳克/毫升增至71.0纳克/毫升,纤溶酶/α2 - 抗纤溶酶复合物从281.5微克/升增至884微克/升,凝血因子XIII从89.0%降至58.5%。所有参数均有显著变化,但接受不同静脉输液的组间反应模式无任何可检测到的差异。在膝关节置换手术期间,无论患者接受晶体液还是胶体液,均观察到凝血/纤溶系统的明显激活。因此,这些结果无法证实晶体液本身在体内会导致高凝状态这一假设。